Related Experiment Videos
Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity?
R M Van den Berg-Vos1, L H Van den Berg, H Franssen
1Department of Neurology, Rudolf Magnus Institute for Neurosciences, University Medical Center Utrecht, The Netherlands.
Neurology
|January 15, 2000
Summary
A newly identified asymmetric demyelinating neuropathy, termed multifocal inflammatory demyelinating neuropathy, affects limbs asymmetrically. This treatable condition shows positive response to IV immunoglobulin therapy.
Area of Science:
- Neurology
- Neuroimmunology
- Peripheral Nervous System Disorders
Background:
- Reports of patients with asymmetric demyelinating neuropathy not meeting criteria for CIDP or MMN exist.
- This highlights a gap in diagnosing and classifying specific neuropathic presentations.
Purpose of the Study:
- To characterize the clinical, electrophysiologic, radiologic, and pathologic features of six patients with asymmetric sensory or sensorimotor demyelinating neuropathy.
- To establish a distinct clinical entity for early diagnosis and treatment.
Main Methods:
- Clinical assessment of six patients with asymmetric neuropathy.
- Electrophysiologic studies to identify demyelination and conduction block.
- MRI of the brachial plexus for imaging abnormalities.
- Histopathological analysis of nerve biopsy.
- Evaluation of treatment response to intravenous immunoglobulin (IVIg).
Main Results:
- All patients presented with unilateral limb involvement, progressing asymmetrically in four cases.
- Electrophysiology confirmed multifocal demyelination and conduction block in all patients.
- MRI revealed nerve swelling and increased T2 signal in the brachial plexus in four patients.
- One patient's biopsy showed inflammation.
- All patients responded well to IVIg treatment, contrasting with previous misdiagnoses of untreatable conditions.
Conclusions:
- The proposed term "multifocal inflammatory demyelinating neuropathy" (MIDN) aims to define this distinct clinical entity.
- Early diagnosis of MIDN is crucial for initiating timely and effective treatment.
- Recognition of MIDN can prevent misdiagnosis and improve patient outcomes.